HCV Inhibitor Compounds for Resistant Genotypes
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current hepatitis C virus (HCV) therapeutic agents have limited effectiveness due to toxicity and side effects, and there is a need for broad-spectrum agents that can target multiple genotypes and are less susceptible to viral resistance.
Innovation Solution
Development of pharmaceutical compositions containing specific compounds, such as those of formula (I), which can be used alone or in combination with other therapeutic agents like ribavirin, NS3 protease inhibitors, or NS5B polymerase inhibitors, to treat HCV, including resistant variants.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If liver-targeting drugs are used to treat hepatitis C, then therapeutic effectiveness is improved, but toxicity and side effects increase
Solution Approach 1:
The patent employs parameter changes by modifying the chemical structure of HCV inhibitors through various substitutions at specific positions (R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, R13, R14, R15, R16, R17, R18, R19, R20, R21, R22, R23, R24, R25, R26, R27, R28, R29, R30, R31, R32, R33, R34, R35, R36, R37, R38, R39, R40, R41, R42, R43, R44, R45, R46, R47, R48, R49, R50) to optimize the balance between therapeutic effectiveness and toxicity reduction
2Reliability
If existing HCV inhibitors are used, then treatment of current genotypes is effective, but viral resistance develops
Solution Approach 1:
The patent achieves universality by designing compounds with a core structure that can effectively target multiple HCV genotypes (1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50) while maintaining stability against viral resistance through strategic substituent placement
Solution Approach 2:
The patent applies composite materials by combining multiple functional groups and substituents (including but not limited to aryl, heteroaryl, alkyl, alkoxy, amino, halo, cyano, nitro, sulfonamido, carboxamido, ester, amide, urea, carbamate, sulfone, sulfoxide, phosphine oxide, boronic acid, silane, germane, stannane, and their derivatives) with the core HCV inhibitor structure to create compounds with enhanced stability and broad-spectrum activity
Data Source
AI summary
The disclosure is related to anti-viral compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as to processes and intermediates useful for preparing such compounds.